- ProQR Announces First Quarter 2024 Operating and Financial Results
- ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic Diseases
- ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024
- ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting
- ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio
- ProQR Announces Year End 2023 Operating and Financial Results
- ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing
- ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024
- ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration
- ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets
More ▼
Key statistics
On Friday, ProQR Therapeutics NV (PRQR:NAQ) closed at 1.94, 74.77% above the 52 week low of 1.11 set on Oct 27, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.94 |
---|---|
High | 2.00 |
Low | 1.93 |
Bid | 1.80 |
Offer | 1.95 |
Previous close | 1.92 |
Average volume | 94.18k |
---|---|
Shares outstanding | 81.35m |
Free float | 63.11m |
P/E (TTM) | -- |
Market cap | 161.08m USD |
EPS (TTM) | -0.3567 USD |
Data delayed at least 15 minutes, as of May 17 2024 21:00 BST.
More ▼